Delivery Order SPE2DB22D1202-SPE2DB25FVFJ4
- Not listed
- The Defense Logistics Agency awarded a $4,831.85 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (10 tablets per dose). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is scheduled for completion by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of UBRELVY 50 mg tablets (10-count unit dose packaging) with a ceiling value of $4,919.80 and an ultimate completion date of August 4, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (16-count) with a ceiling value of $1,375.92. This is a firm fixed price delivery order with no set-aside designation, issued under the agency's competitive procurement processes. The order is set to be completed by August 13, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of UBRELVY 50 mg tablets in unit-dose packaging (10 units per package). This competitive award, valued at $30,906.84, represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 50 mg tablets in unit dose packaging (10 count). This order, valued at $5,439.62 with a firm fixed price structure, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with a...
- The Defense Logistics Agency awarded a delivery order valued at $1,217.32 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10 unit dose packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price delivery order represents a non-set-aside competitive award and reflects the pharmaceutical distribution services AmerisourceBergen provides to federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,270.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets in unit dose packages of 10, valued at $1,595.01. This competitively awarded, firm fixed-price delivery order was issued on July 24, 2025, with an ultimate completion date of July 25, 2025. The contract involves no set-aside designation and identifies AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania as the place of performance. This delivery order...
- The Defense Logistics Agency awarded a $26,179.43 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-count unit dose packaging) on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $2,199.96 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit dose packages) on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVFJ4Delivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packages of 10, with a ceiling value of $7,203.43. This is a firm fixed price delivery order with an ultimate completion date of July 24, 2025, and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreements. The contract was competitively awarded with no set-aside designation, and performance will be conducted from the vendor's location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's broader relationship with the Defense Logistics Agency, which includes a significant Indefinite Delivery Contract valued at $999,999,999.00 through December 2026 that serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies brand-name and generic medications, vaccines, and specialized healthcare commodities to support military and veteran healthcare systems. UBRELVY is indicated for migraine treatment, reflecting the company's role in supplying specialized neurological medications alongside its extensive portfolio of therapeutic products to the Defense Health Agency and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 7/23/25 |